Carbetocin Research Profile: Long-Acting Oxytocin Analog

# Carbetocin Research Profile: Long-Acting Oxytocin Analog

For Research Use Only (RUO). The information in this article is intended for educational and research purposes only. Carbetocin is not approved for use in the United States by the FDA as a standalone pharmaceutical. Researchers working outside the US should consult applicable regulatory frameworks. Nothing here constitutes medical advice, diagnosis, or treatment guidance.

---

What Is Carbetocin?

Carbetocin (INN: carbetocin; brand names Pabal, Duratocin) is a synthetic 1-deamino-1-monocarba octapeptide — a structurally modified analog of the endogenous nonapeptide oxytocin. While oxytocin itself is a nine-amino-acid cyclic peptide containing a disulfide bridge between cysteine residues at positions 1 and 6, carbetocin incorporates two key structural modifications that dramatically extend its biological half-life and duration of action.

Structural Modifications Relative to Oxytocin

The native oxytocin molecule is susceptible to rapid enzymatic cleavage by two enzyme classes:

• •Aminopeptidases, which attack the N-terminal cysteine
• •Disulfidases, which cleave the 1–6 disulfide bridge

Carbetocin addresses both vulnerabilities through targeted chemical engineering:

1. N-terminal desamination — removal of the amino group at position 1 converts cysteine to 1-deaminocysteine (also termed penicillamine-derived desamino residue), blocking aminopeptidase access

2. Disulfide-to-methylene substitution — the 1–6 disulfide bond (Cys¹–Cys⁶) is replaced by a methylene bridge (-CH₂-), rendering it resistant to disulfidase cleavage

The result is a monocarba cyclic octapeptide that retains high affinity for the oxytocin receptor (OTR/OXTR) while exhibiting substantially greater metabolic stability than the parent hormone. This structural chemistry was first reported in 1987 and forms the pharmacological basis for carbetocin's clinical differentiation from oxytocin.

Molecular formula: C₄₅H₆₉N₁₁O₁₂S

Molecular weight: 988.17 g/mol

---

Mechanism of Action: OTR Agonism and Uterotonic Activity

Carbetocin is a selective agonist at the oxytocin receptor (OTR), a class I G protein-coupled receptor (GPCR) expressed in uterine myometrium, mammary gland epithelium, and multiple brain regions including the nucleus accumbens, bed nucleus of the stria terminalis (BNST), and lateral septum.

Receptor Binding and Signal Transduction

Upon binding OTR, carbetocin initiates the canonical Gq/11 signaling cascade:

1. Gq activation → stimulation of phospholipase C-β (PLCβ)

2. PLCβ cleaves phosphatidylinositol 4,5-bisphosphate (PIP₂) into diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP₃)

3. IP₃ triggers calcium (Ca²⁺) release from the sarcoplasmic reticulum

4. Elevated intracellular Ca²⁺ activates myosin light-chain kinase (MLCK), driving smooth muscle contraction

Research published in Neuropsychopharmacology has characterized carbetocin as a functionally biased OTR-Gq agonist and OTR-Gi antagonist — meaning it selectively promotes Gq-mediated excitatory signaling while simultaneously inhibiting the inhibitory Gi pathway. This biased agonism profile distinguishes carbetocin from oxytocin and may underlie some of its distinct behavioral pharmacology in preclinical research models.

Uterotonic Effects

In the myometrium, OTR density increases dramatically during late gestation under estrogen priming. Carbetocin binding produces:

• •Rhythmic uterine contractions
• •Increased frequency and amplitude of existing contractions
• •Sustained elevation of baseline uterine tone

These effects are directly comparable to oxytocin but are significantly more prolonged due to carbetocin's superior metabolic stability.

---

Published Pharmacokinetic Parameters

The pharmacokinetic profile of carbetocin is well-characterized from multiple clinical and veterinary studies, and provides the quantitative basis for its clinical advantages over oxytocin.

The IV half-life of 40–100 minutes reported in the literature reflects interindividual variability and differing analytical methods across studies. The frequently cited figure of ~42 minutes originates from pharmacokinetic modeling in clinical populations. By contrast, oxytocin's half-life of 4–10 minutes necessitates continuous infusion to maintain sustained uterotonic activity — a key logistical disadvantage in resource-limited settings.

Carbetocin's extended half-life results from its resistance to both aminopeptidase and disulfidase degradation pathways. Urinary excretion accounts for the majority of elimination, with only a small fraction of unchanged drug recovered (indicating hepatic and/or tissue-level metabolism contributes to clearance).

Veterinary PK data: A 2020 PubMed study (PMID 31856330) characterized carbetocin pharmacokinetics in cattle and gilts following IV and IM administration, demonstrating species-consistent resistance to degradation and confirming the peptide's metabolic stability across mammalian systems.

---

Research Applications

1. Postpartum Hemorrhage Prevention

Carbetocin's primary and most extensively studied clinical application is in the prevention of postpartum hemorrhage (PPH), the leading cause of maternal mortality worldwide — responsible for approximately 27% of maternal deaths globally.

#### The CHAMPION Trial

The landmark CHAMPION (Carbetocin Haemorrhage Prevention) trial, conducted by the WHO in collaboration with Ferring Pharmaceuticals and Merck for Mothers, enrolled 29,645 women from 23 sites across 10 countries (Argentina, Egypt, India, Kenya, Nigeria, Singapore, South Africa, Thailand, Uganda, and the UK). Published in the New England Journal of Medicine, the trial randomized participants to receive either carbetocin 100 µg IM or oxytocin 10 IU IM immediately following vaginal delivery.

Key finding: Carbetocin demonstrated non-inferiority to oxytocin for PPH prevention. The incidence of blood loss ≥500 mL or use of additional uterotonics was 14.5% in the carbetocin group versus 14.4% in the oxytocin group — a statistically non-significant difference meeting the pre-specified non-inferiority margin.

A 2024 secondary analysis (PMID 37357606, published in the International Journal of Gynecology & Obstetrics) examined whether non-inferiority held across high-risk subgroups — women with macrosomia, parity ≥3, prior PPH history, or induction/augmentation. The analysis confirmed that carbetocin's performance was consistent regardless of these biologic or pharmacologic risk factors.

#### Network Meta-Analysis Evidence

Beyond the CHAMPION trial, network meta-analyses of randomized controlled trials have demonstrated that carbetocin reduces the need for additional uterotonic agents compared with oxytocin alone (RR 0.48, 95% CI 0.34–0.68) and shows superiority for reducing blood loss ≥500 mL (RR 0.75, 95% CI 0.58–0.98) when accounting for quality and route factors.

2. Social Behavior and Neuroscience Research

Because carbetocin shares the same receptor target as oxytocin (often called the "bonding hormone"), it is increasingly used as a pharmacological tool in preclinical neuroscience research exploring the OTR system's role in social cognition, affiliative behavior, and anxiety.

As a biased Gq agonist, carbetocin enables researchers to dissect the specific signaling contributions of OTR-Gq versus OTR-Gi pathways to behavioral outcomes — a level of mechanistic resolution not possible with native oxytocin.

Published research findings include:

• •Nucleus accumbens: Carbetocin microinjection increased social approach in stressed female rodents and attenuated social vigilance, consistent with pro-affiliative OTR-Gq activation in reward circuitry (Neuropsychopharmacology, 2020)
• •BNST (bed nucleus of the stria terminalis): Carbetocin's OTR-Gq selectivity modulates social interaction in a cell-type-dependent manner, with Cyp26b1-expressing neurons showing high Oxtr expression in anterior BNST regions (ScienceDirect, 2022)
• •Lateral septum: Paradoxically, carbetocin microinjection into the caudolateral septum reduced social approach and social discrimination memory in both sexes, and produced anxiogenic effects specifically in males — highlighting brain-region-dependent heterogeneity in OTR-Gq signaling outcomes
• •Pair bonding: OTR agonism in prairie vole models (an established rodent paradigm for pair bond research) demonstrates the receptor's central role in partner preference formation, with OTR density in the nucleus accumbens correlating with species-typical monogamy patterns

This body of research positions carbetocin as a valuable tool compound for dissecting OTR signaling pathways in the context of social neuroscience, anxiety, and potential therapeutic development for conditions involving social deficits (e.g., autism spectrum disorder, social anxiety disorder).

3. Receptor Selectivity Research

Carbetocin's biased agonism profile also makes it useful for comparative OTR pharmacology studies. While native oxytocin activates both OTR and vasopressin V1a receptors (due to structural similarity between the two peptide systems), carbetocin shows preferential OTR selectivity — though emerging research on newer analogs (e.g., dOTmeta) suggests even greater OTR selectivity is achievable through further structural refinement.

---

Stability and Storage: The Heat-Stable Advantage

A critical practical advantage of carbetocin in clinical and research contexts is its thermostability. Standard oxytocin requires cold-chain storage (2–8°C), which is difficult to maintain reliably in low- and middle-income countries (LMICs) with limited refrigeration infrastructure.

Heat-Stable Formulation

The WHO-approved formulation of heat-stable carbetocin (HSC) maintains potency at ambient temperatures, eliminating cold-chain dependency. This property directly addresses one of the primary implementation barriers for uterotonic distribution in LMICs and was a key rationale for carbetocin's inclusion on the WHO Model List of Essential Medicines.

Following the CHAMPION trial results, the WHO added heat-stable carbetocin to the Essential Medicines List (EML), recognizing it as an equivalent uterotonic to oxytocin with superior storage characteristics. Nigeria updated its national PPH guidelines in 2024 to include HSC; Kenya and India had already incorporated it into maternal health protocols following their CHAMPION trial participation.

Research-Grade Storage

For research applications, carbetocin is typically supplied as:

• •Lyophilized powder — most stable form; reconstitute in sterile water or physiological buffer immediately before use
• •Solution formulations — refrigerate at 2–8°C; protect from light; avoid repeated freeze-thaw cycles

Typical research-grade purity specifications: ≥98% by HPLC. Lot-specific certificates of analysis (CoA) should confirm purity, identity (mass spectrometry confirmation), and absence of endotoxins for in vivo applications.

---

Research Considerations: Advantages of OTR Selectivity

For researchers working within the oxytocin/vasopressin system, carbetocin offers several methodological advantages:

The Gq-biased pharmacology enables mechanistic dissection studies where researchers can attribute behavioral or physiological outcomes specifically to OTR-Gq signaling. The longer half-life also simplifies single-dose experimental designs, reducing the procedural complexity associated with maintaining oxytocin infusions in animal studies.

---

Regulatory and Approval Status

Carbetocin is approved in multiple jurisdictions for the prevention of uterine atony and PPH following cesarean section and vaginal delivery:

• •Canada — approved (Duratocin, Carbetocin Injection); widely used in obstetric practice
• •European Union — approved (Pabal); labeled for cesarean section under epidural/spinal anesthesia
• •Multiple LMICs — incorporated into national essential medicine formularies following WHO EML listing
• •United States — not approved by the FDA as a standalone therapeutic agent; not commercially available in the US market

Researchers in the United States should note that carbetocin obtained for research purposes falls under Research Use Only (RUO) classification and is not intended for human therapeutic administration.

---

Supplier Selection for Research-Grade Carbetocin

Selecting a qualified supplier is critical for reproducible research outcomes. Key criteria for research-grade carbetocin procurement:

Quality indicators:

• •≥98% purity verified by HPLC (not RP-HPLC alone; confirm with mass spec identity check)
• •Lot-specific CoA available for download or on request
• •Endotoxin testing report for in vivo-intended material (LAL assay)
• •Proper CAS number documentation: CAS 37025-55-1

Sourcing considerations:

• •Confirm the vendor supplies the correct structural form (1-deamino-1-monocarba modification, not oxytocin mislabeled)
• •For behavioral neuroscience applications, verify sterility and pyrogen testing if central microinjection is planned
• •For PPH research models, pharmaceutical-grade carbetocin from licensed API suppliers is preferable

Use the Peptides.SO supplier comparison tool to evaluate verified research-grade peptide suppliers. The peptide dosage calculator can assist with reconstitution and concentration calculations for laboratory protocols.

For context on the related endogenous peptide system and receptor pharmacology, see our comprehensive oxytocin research profile.

---

Key Takeaways for Researchers

• •Carbetocin is a 1-deamino-1-monocarba oxytocin analog with a half-life 4–10× longer than oxytocin due to resistance to aminopeptidase and disulfidase cleavage
• •Biased OTR-Gq agonism enables mechanistic dissection of OTR signaling pathways in social behavior and uterotonic research
• •CHAMPION trial (n=29,645) established non-inferiority to oxytocin for PPH prevention; 2024 secondary analysis confirmed consistent performance across high-risk subgroups
• •Heat-stable formulation on WHO Essential Medicines List addresses cold-chain barriers in LMICs
• •Not FDA-approved in the United States; for research use only in US contexts
• •Source from reputable suppliers with lot-specific CoA, HPLC purity ≥98%, and endotoxin data for in vivo applications

---

This article is intended for educational and research purposes only (RUO). Carbetocin is not approved as a pharmaceutical in the United States. This content does not constitute medical advice, and should not be used to guide clinical decision-making. Researchers should comply with all applicable institutional and regulatory guidelines when working with peptide compounds.

---

References

1. Ghosh S, et al. "Heat stable carbetocin or oxytocin for prevention of postpartum hemorrhage among women at risk: A secondary analysis of the CHAMPION trial." Int J Gynecol Obstet. 2024; PMID 37357606.

2. Ohlsson AI, et al. "Carbetocin for prevention of postpartum hemorrhage: a systematic Cochrane review." J Matern Fetal Neonatal Med. 2020.

3. Magon N, Chauhan M. "Carbetocin in prevention of postpartum hemorrhage: a boon for low resource settings." Niger Med J. 2012.

4. Einspanier A, et al. "Pharmacokinetics and bioavailability of carbetocin after intravenous and intramuscular administration in cows and gilts." J Vet Pharmacol Ther. 2020; PMID 31856330.

5. PMC12145113: "Heat-Stable Carbetocin in the Management of Postpartum Haemorrhage in Low- and Middle-Income Countries." PMC, 2025.

6. Bhatt DL, et al. CHAMPION Trial. New England Journal of Medicine. 2018.

7. Smith AS, et al. "Social approach and social vigilance are differentially regulated by oxytocin receptors in the nucleus accumbens." Neuropsychopharmacology. 2020.

8. Jurek B, Neumann ID. "The Oxytocin Receptor: From Intracellular Signaling to Behavior." Physiol Rev. 2018; 98(3):1805–1908.